Palvella Therapeutics (PVLA) Free Cash Flow Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 24.91% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 20.11% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.71% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -10.65% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 31.42% |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | 0.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.44% |
| Dec 31, 2025 | 29.34% |
| Sep 30, 2025 | 3.59% |
| Jun 30, 2025 | 29.18% |
| Mar 31, 2025 | 33.43% |
| Dec 31, 2024 | 23.17% |
| Sep 30, 2024 | 42.24% |
| Jun 30, 2024 | -27.12% |
| Mar 31, 2024 | 55.09% |
| Dec 31, 2023 | 51.46% |
| Sep 30, 2023 | -13.47% |
| Jun 30, 2023 | -7.48% |
| Mar 31, 2023 | 13.49% |
| Dec 31, 2022 | 2.73% |
| Sep 30, 2022 | 11.95% |
| Jun 30, 2022 | -9.45% |
| Mar 31, 2022 | -14.63% |
| Dec 31, 2021 | -7.31% |
| Sep 30, 2021 | 1.05% |
| Jun 30, 2021 | 72.84% |
| Mar 31, 2021 | -33.76% |
| Dec 31, 2020 | -36.41% |
| Sep 30, 2020 | -29.92% |
| Jun 30, 2020 | -14.69% |
| Mar 31, 2020 | -38.67% |
| Dec 31, 2019 | -29.56% |
| Sep 30, 2019 | -50.58% |
| Jun 30, 2019 | -23.68% |
| Mar 31, 2019 | -113.82% |
| Dec 31, 2018 | -50.14% |
| Sep 30, 2018 | -57.87% |
| Jun 30, 2018 | -44.38% |
| Mar 31, 2018 | 119.05% |
| Sep 30, 2017 | 1,259.06% |
| Jun 30, 2017 | -28.18% |
| Mar 31, 2017 | 297.69% |
| Dec 31, 2016 | -1,844.18% |
| Sep 30, 2016 | -842.16% |
| Jun 30, 2016 | -2,723.35% |